The effects of statins on the clinical outcomes of Clostridium difficile infection in hospitalised patients

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 6, 2013, Pages 619-627

  Park, S W ^a   Choi, A R ^a   Lee, H J ^a   Chung, H ^a   Park, J C ^a   Shin, S K ^a   Lee, S K ^a   Lee, Y C ^a   Kim, J E ^b   Lee, H ^a  

^a Yonsei University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METRONIDAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CONVALESCENCE; DISEASE SEVERITY; DRUG EFFECT; DRUG EXPOSURE; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT OUTCOME;

EID: 84883054927     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12439     Document Type: Article

References (42)

1. McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK,. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007; 28: 140-5.
2. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN,. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012; 107: 1001-10.
3. Archibald LK, Banerjee SN, Jarvis WR,. Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001. J Infect Dis 2004; 189: 1585-9.
4. Turco R, Martinelli M, Miele E, et al,. Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection. Aliment Pharmacol Ther 2010; 31: 754-9.
5. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK,. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012; 107: 1011-9.
6. Yearsley KA, Gilby LJ, Ramadas AV, Kubiak EM, Fone DL, Allison MC,. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment Pharmacol Ther 2006; 24: 613-9.
7. Dalton BR, Lye-Maccannell T, Henderson EA, Maccannell DR, Louie TJ,. Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting. Aliment Pharmacol Ther 2009; 29: 626-34.
8. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA,. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010; 170: 772-8.
9. Motzkus-Feagans CA, Pakyz A, Polk R, Gambassi G, Lapane KL,. Statin use and the risk of Clostridium difficile in academic medical centres. Gut 2012; 61: 1538-42.
10. Falagas ME, Makris GC, Matthaiou DK, Rafailidis PI,. Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother 2008; 61: 774-85.
11. Al Harbi SA, Tamim HM, Arabi YM,. Association between statin therapy and outcomes in critically ill patients: a nested cohort study. BMC Clin Pharmacol 2011; 11: 12.
12. Rothberg MB, Bigelow C, Pekow PS, Lindenauer PK,. Association between statins given in hospital and mortality in pneumonia patients. J Gen Intern Med 2012; 27: 280-6.
13. Nseir W, Mograbi J, Abu-Elheja O, Bishara J, Assy N,. The impact of prior long-term versus short-term statin use on the mortality of bacteraemic patients. Infection 2012; 40: 41-8.
14. Charlson ME, Sax FL, MacKenzie CR, Fields SD, Braham RL, Douglas RG Jr,. Assessing illness severity: does clinical judgment work? J Chronic Dis 1986; 39: 439-52.
15. Gravel D, Miller M, Simor A, et al,. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis 2009; 48: 568-76.
16. Gerding DN, Olson MM, Peterson LR, et al,. Clostridium difficile-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. Arch Intern Med 1986; 146: 95-100.
17. Wanahita A, Goldsmith EA, Marino BJ, Musher DM,. Clostridium difficile infection in patients with unexplained leukocytosis. Am J Med 2003; 115: 543-6.
18. Kirkpatrick ID, Greenberg HM,. Evaluating the CT diagnosis of Clostridium difficile colitis: should CT guide therapy? AJR Am J Roentgenol 2001; 176: 635-9.
19. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB,. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2007; 45: 302-7.
20. Belmares J, Gerding DN, Parada JP, Miskevics S, Weaver F, Johnson S,. Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect 2007; 55: 495-501.
21. Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC,. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000; 38: 2386-8.
22. O'Connor JR, Johnson S, Gerding DN,. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 2009; 136: 1913-24.
23. Leonard J, Marshall JK, Moayyedi P,. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102: 2047-56.
24. Almog Y, Shefer A, Novack V, et al,. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004; 110: 880-5.
25. Hackam DG, Mamdani M, Li P, Redelmeier DA,. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006; 367: 413-8.
26. Arnaud C, Veillard NR, Mach F,. Cholesterol-independent effects of statins in inflammation, immunomodulation and atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5: 127-34.
27. Naggie S, Miller BA, Zuzak KB, et al,. A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors. Am J Med 2011; 124: 276.
28. Remick DG,. Pathophysiology of sepsis. Am J Pathol 2007; 170: 1435-44.
29. Liappis AP, Kan VL, Rochester CG, Simon GL,. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 2001; 33: 1352-7.
30. Janda S, Young A, Fitzgerald JM, Etminan M, Swiston J,. The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis. J Crit Care 2010; 25: 656.
31. Thomsen RW, Hundborg HH, Johnsen SP, et al,. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med 2006; 34: 1080-6.
32. Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W,. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22: 813-8.
33. Pepin J, Valiquette L, Alary ME, et al,. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171: 466-72.
34. Fernandez A, Anand G, Friedenberg F,. Factors associated with failure of metronidazole in Clostridium difficile-associated disease. J Clin Gastroenterol 2004; 38: 414-8.
35. Nair S, Yadav D, Corpuz M, Pitchumoni CS,. Clostridium difficile colitis: factors influencing treatment failure and relapse-a prospective evaluation. Am J Gastroenterol 1998; 93: 1873-6.
36. Pepin J, Routhier S, Gagnon S, Brazeau I,. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006; 42: 758-64.
37. Do AN, Fridkin SK, Yechouron A, et al,. Risk factors for early recurrent Clostridium difficile-associated diarrhea. Clin Infect Dis 1998; 26: 954-9.
38. Anand A, Bashey B, Mir T, Glatt AE,. Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea. Am J Gastroenterol 1994; 89: 519-23.
39. Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME,. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997; 24: 324-33.
40. Nseir W, Bishara J, Mograbi J, et al,. Do statins protect against the development of Clostridium difficile-associated diarrhoea? J Antimicrob Chemother. 2013; 68: 1889-93.
41. Bricker E, Garg R, Nelson R, Loza A, Novak T, Hansen J,. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev. 2005; CD004610.
42. Almog Y, Novack V, Eisinger M, Porath A, Novack L, Gilutz H,. The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Crit Care Med 2007; 35: 372-8.